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Abstract
mTOR is a highly conserved serine/threonine protein kinase that is critical for diverse cellu-
lar processes in both developmental and physiological settings. mTOR interacts with a set
of molecules including Raptor and Rictor to form two distinct functional complexes, namely
the mTORC1 and mTORC2. Here, we used novel genetic models to investigate functions of
the mTOR pathway for cranial neural crest cells (NCCs), which are a temporary type of cells
arising from the ectoderm layer and migrate to the pharyngeal arches participating craniofa-
cial development. mTOR deletion elicited a proliferation deficit and excessive apoptosis of
post-migratory NCCs, leading to growth arrest of the facial primordia along with midline oro-
facial clefts. Furthermore, NCC differentiation was impaired. Thus, NCC derivatives, such
as skeletons, vasculatures and neural tissues were either rudimentary or malformed. We
further demonstrate that disruption of mTOR caused P53 hyperactivity and cell cycle arrest
in cranial NCCs, and lowering P53 activity by one copy reduction attenuated the severity of
craniofacial phenotype in NCC-mTOR knockout mice. Remarkably, NCC-Rptor disruption
caused a spectrum of defects mirroring that of the NCC-mTOR deletion, whereas NCC-Ric-
tor disruption only caused a mild craniofacial phenotype compared to the mTOR and Rptor
conditional knockout models. Altogether, our data demonstrate that mTOR functions medi-
ated by mTORC1 are indispensable for multiple processes of NCC development including
proliferation, survival, and differentiation during craniofacial morphogenesis and organogen-
esis, and P53 hyperactivity in part accounts for the defective craniofacial development in
NCC-mTOR knockout mice.
Author summary
mTOR is a highly conserved serine/threonine protein kinase that plays critical roles
in diverse processes. mTOR acts through forming two distinct functional complexes,
namely the mTORC1 and mTORC2. In this study, we generated novel genetic models to
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investigate the functions of the mTOR pathway for neural crest cell (NCC), which is an
important embryonic cell type for craniofacial development. Disruption of mTOR elicited
a proliferation deficit and excessive cell death of post-migratory NCCs, leading to facial
growth deficiency and orofacial clefts. Furthermore, NCC differentiation was impaired
and NCC derivatives, such as skeletons, vasculatures and neural tissues were either rudi-
mentary or malformed. We also found that disruption of mTOR caused P53 hyperactivity,
and lowering P53 activity ameliorated the craniofacial phenotype seen in NCC-mTOR
knockout mice, suggesting that P53 hyperactivity might in part account for the craniofa-
cial defects in mutant mice. Remarkably, disruption of mTORC1 by deletion of the gene
encoding the core component Raptor caused a spectrum of defects mirroring that of the
NCC-mTOR knockout mice, suggesting that mTOR regulates NCC development princi-
pally through the mTORC1 pathway during embryogenesis.
Introduction
Initiation of craniofacial morphogenesis is marked by the appearance of the paired pharyngeal
arches (PAs). The first pair of PAs are further divided into paired mandibular and maxillary
prominences, which together with the single frontonasal prominence (FN) constitute the five
facial primordia. The facial primordia expand rapidly and unify to form a continuous face. An
important cell type in this process is the cranial neural crest cells (NCCs), which are stem-cell-
like cells formed at the border of the non-neural ectoderm and the developing brain, including
the hindbrain, midbrain and posterior portion of the forebrain [1–4]. Cranial NCCs, upon
induction, delaminate from the dorsal edge of the developing brain, migrate bilaterally along
delicately organized paths, colonize at the ventral portion of the brain, and drive the budding
of the five pairs of PAs and the single FN in mammals [1–4].
Post-migratory NCCs are highly dynamic in spatial distribution in response to local
developmental cues, and proliferate vigorously to promote the rapid expansion of PAs and
derivation of the facial primordia. Meanwhile, NCCs interact with local epithelial cells and
mesoderm-derived mesenchymal cells to initiate organogenesis in the majority of craniofacial
organ systems. The majority of cranial NCCs eventually commit to a fate decision depending
on a specific developmental context and differentiate into a variety of cell types, including
chondroblasts, osteoblasts, odontoblasts, melanocytes, vascular smooth muscle cells (SMCs),
glial cells and neurons to form cartilages, bones, dentin, vascular smooth muscles and neural
tissues [5]. Even though, a number of NCCs retain their stemness to maintain a stem cell pool
in continuous development [3].
NCC development is finely controlled by a complex molecular network. Multiple lines of
evidence indicate that the mammalian target of rapamycin (mTOR), which is a highly con-
served serine/threonine protein kinase belonging to the phosphoinositide 3-kinase (PI3K)-
related kinase family and integrates a myriad of signals for cell function, is potentially
important for NCC development [6–10]. mTOR maintains tissue and organ homeostasis by
regulating a variety of cellular processes, including proliferation, apoptosis, differentiation,
metabolism, autophagy and aging. mTOR interacts with a set of molecules, including Raptor
and Rictor, to form two distinct functional complexes, namely the mTORC1 and mTORC2 [7,
8, 11]. In physiological settings, mTORC1 senses diverse intracellular and extracellular cues,
including signals of growth factors and amino acids, and regulates various cellular activities
through phosphorylating eukaryotic translation initiation factor 4E (eIF4E) binding protein 1
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(4E-BP1) and S6 kinase 1 (S6K1), which are critical for protein synthesis and ribosome biogen-
esis [6–9]. mTORC2 positively regulates mTORC1 through regulating Akt signaling [11–13].
Developmental roles of mTOR have been extensively studied in recent years. Germline dis-
ruption of mTOR in mice leads to embryonic death at the implantation stage [14]. Disruption
of either Rptor or Rictor also causes early embryonic death prior to craniofacial organogenesis,
demonstrating that mTORC1 and mTORC2 are both critical for early embryonic development
[12, 15]. Conditional knockout (cKO) approaches have unveiled critical functions of the
mTOR pathway in a variety of organs including the brain, lung, heart, skin, muscle and skele-
ton [10, 16–20]. In addition, mTOR is also important for maintaining the stemness of various
types of stem cells, and aberrant mTOR activities are implicated in diverse pathological condi-
tions [7, 21, 22].
In the dental-craniofacial complex, functions of the mTOR pathway are less recognized.
Recent studies indicate that mTOR is critical for craniofacial development. Disruption of
mTOR in mesoderm-derived mesenchymal cells not only disrupts long bone development but
also causes calvarial defects [10]. By contrast, hyperactivity of mTOR in NCCs caused by dis-
ruption of TSC1, whose product binds to TSC2 to suppress mTORC1 activity, leads to sclerosis
in NCC-derived bones [23]. In spite of the potential significance of the mTOR pathway for
NCCs, there still lacks direct evidence to assign a functional role for mTOR in NCC develop-
ment. Here, we generated NCC-specific knockout models for the mTOR pathway using a
widely used Cre strain containing the Wnt1-cre transgene, which specifically targets the major-
ity of the pre-migratory NCCs if not all, and hence their descendants in the target organs [24].
We demonstrate that mTOR is indispensable for post-migratory NCC proliferation, survival
and differentiation, and mTOR acts largely through mTORC1 during embryogenesis. Further-
more, mTOR deficiency induces P53 hyperactivity in NCCs.
Results
p-mTOR dynamics in cranial NCCs and their derivatives
NCC migration from the interface of the ectoderm and developing brain starts around E8.5
and completes during E9.5 to E10.5 in mice (Fig 1A). At E9.0, p-mTOR was observed in
migrating NCCs at a high level, as indicated by co-localization of p-mTOR with a NCC
marker AP2-α (Fig 1B). It also showed ubiquitous activation in the first pair of PAs, which
are predominately composed of post-migratory NCCs (Fig 1A; S1 Fig)[25]. One day later, p-
mTOR continued to maintain a high level in the expanding facial primordia, including the
paired mandibular and maxillary prominences and the single FN, which are still largely pop-
ulated by NCCs (Fig 1C–1H). During E11.5 to E12.5, when organogenesis has initiated in
multiple systems, p-mTOR was found in mesenchymal condensates of the mandible and in
neural tissues at high levels (S1 Fig; Fig 1I–1K). At mid-gestation, p-mTOR was found in
NCC–derived bones and cartilages at medium levels (S1 Fig). Additionally, it was also seen
in the craniofacial muscles, which are not derived from NCCs (S1 Fig). By contrast, p-
mTOR levels in the first pair of PAs of the Wnt1-cre;mTOR loxp/loxp cKO mice were markedly
reduced, indicating that mTOR had been successfully disrupted by Cre-mediated recombina-
tion (Fig 1L, 1M and 1N).
Disruption of mTOR causes defective craniofacial morphogenesis
Next, we performed detailed phenotypic study on Wnt1-cre;mTOR loxp/loxp cKO mice. The
majority of Wnt1-cre;mTOR loxp/loxp cKO mice died at E12.5, with very few survived to E14.5
(found at a ratio of 3%, expected at 25%). By E11.5, Wnt1-cre;mTOR loxp/loxp cKO mice could be
visually recognized by changes in craniofacial morphology. At this stage, growth of the five
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Fig 1. mTOR dynamics during craniofacial development. (A) Whole mount LacZ staining of Wnt1-cre; Rosa26R
embryos. White lines indicate the sectioning planes in relevant images. (B) Immunofluorescence for Ap2-α and p-
mTOR in the migrating NCCs at E9.0. (C, D; F, G) Immunofluorescence for p-mTOR in the FN and mandibular
prominences at late E10.5. (E, H) Sections of a Lac-Z-stained E10.5 heads, showing NCC distribution in the FN and
mandibular prominence. (I, J, K) Co-localization of p-mTOR with a neurofilament marker 3A10. (L, M)
Immunofluorescence for p-mTOR in the mandibular prominence of E10.5 mice. (N) Quantification of p-mTOR levels
of the mandibular prominences by calculating relative fluorescence intensity, p<0.01. br: brain; ctr: control; fn:
frontonasal prominence; cko: conditional knockout; md: mandibular prominence; md.b: mandibular branch of
trigeminal nerve; mx: maxillary prominence; ne: nasal epithelium; nt: neural tube; tg: trigeminal ganglion; ton: tongue.
Scale bar in (A): 200 μm; Scale bars in others: 100 μm.
https://doi.org/10.1371/journal.pgen.1007491.g001
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facial primordia in mutants was markedly delayed compared to controls, as evidenced by
hypoplasia of mutant facial primordia (Fig 2A and 2B). The FN prominences failed to expand
to the midline (Fig 2A and 2B). Thereafter, development of facial primordia was arrested and
midline facial cleft persisted in mutants with full penetrance (Fig 2A, 2B and 2C). Histologic
examination revealed defective organogenesis in multiple organ systems, including the palate,
tongue, tooth, and skeleton (Fig 2D–2G). Despite of these defects, a considerable number of
NCCs survived in mutant facial primordia, as indicated by distribution of GFP-labelled NCCs
in the Wnt1-cre; mTOR loxp/loxp; Rosa nT-nG mice (Fig 2B).
Bmp and Wnt signaling was obviously impaired in mutants, as indicated by reduced levels
of p-Smad1/5/8 and β-catenin in NCC condensates (Fig 2H–2L). Staining of NCC marker
Alx3, Msx1, and Pax3 showed reduced expression in mutant facial primordia, suggesting that
NCCs changed in gene expression (Fig 2M–2P and 2R). Expression of epithelial marker Fgf8
remained comparable to the control, suggesting that epithelium development was virtually
normal at this stage (Fig 2Q and 2R).
Defective organogenesis in multiple systems in mTOR cKO mutant mice
NCCs also contribute to neural tissues [1–4]. Whole mount staining with a neurolfilament
marker 3A10 revealed reduced dimensions of mutant trigeminal ganglion and its branches at
E10.5 (Fig 3A and 3B). By E12.5, the mandibular branch of mutant trigeminal nerve failed to
reach the anterior segment of the mandibular arch, while the maxillary branch showed fewer
neural fibers in mutants than in controls (Fig 3C and 3D).
The salivary glands and teeth are formed via continuous epithelial-mesenchymal interac-
tions, and the mesenchymal tissue is principally of NCC origin [1–4]. Here we found that
development of submandibular and sublingual glands in mTOR mutants was delayed, as
evidenced by smaller sizes and fewer numbers of epithelial branching events than controls
(Fig 3E and 3F, S2 Fig). Molar development in mutants failed to proceed beyond the bud stage
(S2 Fig).
NCCs express Vegf and regulate angiogenesis and vasculogenesis during craniofacial devel-
opment [26]. Examination of craniofacial vasculature with endothelial marker CD31 revealed
that vascular structures were abundant in controls but few in mutants at E12.5, suggesting that
disruption of mTOR in NCCs causes microvascular rarefaction (Fig 3G and 3H). α-SMA stain-
ing showed that vascular SMC layers were often malformed and discontinuous in mutants,
thus vessel dilation and bleeding were common (Fig 3I and 3J). These results indicate that
mutant SMCs were functionally insufficient.
NCCs also regulate mesoderm-derived tissues via diverse signal pathways [27–30].
The tongue, which is largely composed of mesoderm-derived muscles, was malformed in
mutants. Mutant tongue bud was hypoplastic and displayed a groove in the midline (Fig 2D–
2G). α-SMA and vimentin staining revealed disorganized tongue muscles in mutants (Fig
3I–3M).
Defective osteogenesis and chondrogenesis in mTOR mutants
Craniofacial bones and cartilages, including the upper and lower jaws, frontal bone, anterior
cranial base (ethmoid and sphenoid bones), nasal cartilages, and the Meckel’s cartilage were all
derived of NCCs [1–4]. Histology and picrosirius red staining failed to reveal any bone tissue
in mutant face up to E14.5 (Figs 2F, 2G, 3M and 3N). Staining for osteogenic markers revealed
that cells in mutant face were positive for early osteogenic marker alkaline phosphatase (ALP)
and Runx2, but negative for terminal osteogenic marker osteocalcin (OCN) (Fig 3O–3X).
These results together indicate that mutant NCCs that had committed to the osteogenic fate
mTOR for Neural crest cells
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Fig 2. Defective craniofacial morphogenesis and organogenesis in the NCC-mTOR KO mice. (A) Craniofacial morphogenesis at two successive stages.
Arrowheads point to facial cleft. (B) Lateral view of E11.5 heads, NCCs are GFP-labeled. (C) SEM examination of E12.5 heads,  marks facial cleft. (D, E)
Histology of E11.5 heads, showing failed midline fusion of the mutant FNs. (F, G) Histology of E14.5 heads. (H-K) Immunofluorescence for β-catenin and
p-Smad1/5/8, arrowheads point to positive staining in the mandibular prominences. (L) Quantification of β-catenin and p-Smad1/5/8 levels by calculating
relative fluorescence intensity. (M-Q) Whole mount in situ hybridization for Alx3, Msx1, Pax3 and Fgf8. (R) Quantification of in situ hybridization
staining of Alx3, Msx1, Pax3 and Fgf8. P<0.05;  P<0.01. br: brain; ctr: control; fn: frontonasal prominence; md: mandibular prominence; mx: maxillary
prominence; ns: non-significant; pal: palate; sn: snout; tb: tooth bud; ton: tongue; vs: vessel. Scale bar in (A-C): 100 μm; scale bar in (A) applies to (M-Q);
scale bars in others: 200 μm.
https://doi.org/10.1371/journal.pgen.1007491.g002
mTOR for Neural crest cells
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007491 July 5, 2018 6 / 21
failed in terminal differentiation. Alcian blue staining showed that the NCC-derived cartilages,
including the anterior basicranium, the Meckel’s cartilage and nasal cartilage, were either miss-
ing or extremely rudimentary (Fig 3O–3T). Furthermore, the master chondrogenesis marker
Sox9 was not detected or barely detectable in mutant facial primordia, suggesting a failure of
chondrogenic differentiation (Fig 3Y and 3Z).
Fig 3. Defective organogenesis in multiple organ systems. (A, B) Whole mount staining for neurofilament marker 3A10 at E10.5. (C, D) Immunofluorescence for
3A10 at E12.5. (E, F) Development of submandibular glands at E12.5, examined under a stereomicroscope. (G, H) Immunofluorescence for CD31 and α-SMA at
E12.5. (I, J) Immunofluorescence for α-SMA at E13.5. Note, severe dilation of the oro-craniofacial vessels in the mutant. (K, L) Immunofluorescence for vimentin at
E14.5. (M, N) Picrosirius red staining at E14.5 reveals absence of maxilla and mandible in the mutant. (O-T) Alcian blue and ALP double staining shows absence of
cartilages (arrow heads) and bones in mutants. (U-Z) Immunofluorescence for Runx2, OCN and Sox9 in the mandibular arch. A.Blue: alcian blue; bo: basioccipital
cartilage; br: brain, bs: basosphenoid cartilage; ctr: control; mc: the Meckel’s cartilage; md: mandibular arch; md.B: mandible branch; ml: molar; max: maxilla; max.B:
maxillary branch; oph.B: ophthalmic branch; pl (ps in G and H): palate; slg: sublingual gland; smg: submandibular gland; ton: tongue; vs: vessel. Scale bar in (A, B):
200 μm; scale bar in others: 100 μm; Scale bar in (K) applies to (M-Z).
https://doi.org/10.1371/journal.pgen.1007491.g003
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NCC migration and early PA morphogenesis were virtually normal in
mTOR cKO mutants
Next, we examined if NCC migration was affected in mutants using Wnt1-cre; mTOR loxp/loxp;
Rosa nT-nG mice, in which NCCs and their derivatives were GFP-labelled. At E9.0, when NCC
migration had started, we observed comparable amounts of GFP-labeled NCCs on their migra-
tion paths and in the first pair of PAs in mutants and stage-matched littermate controls (Fig 4A–
4C). Mice at E9.5 and E10.5 also displayed comparable NCC distribution in the PAs and facial
primordia of the two genotypes (Fig 4D–4J). Altogether, these results indicate that initial migra-
tion and early development of cranial NCCs and PAs were virtually unaffected in mutants.
Increased apoptosis and reduced cell proliferation in mutant facial
primordia
TUNEL staining revealed slightly increased apoptosis in mesenchyme of mutant facial primor-
dia at E10.5 (Fig 5A and 5B). By E11.5, apoptosis was markedly increased in mutants (Fig 5C,
5D and 5E). By co-localization of apoptotic cells with Runx2+ cells, we demonstrated that apo-
ptotic cells were principally NCC-derived cells that had been committed to the osteogenic fate
(Fig 5F and 5F’).
Reduced cell proliferation was already obvious at E10.5 in mutant facial primordia, demon-
strated by staining of a mitosis marker phospho-histone H3 (PHH3) (Fig 5G and 5H). At
E11.5, very few mitotic cells were detected in mutant FNs and other facial primordia, relative
to vigorous cell mitosis in controls (Fig 5I–5M). Moreover, we observed reduced cell prolifera-
tion in mutant tongue bud, which is largely composed of mesoderm-derived muscular precur-
sors, suggesting that multiple cell lineages were affected (Fig 5K and 5L).
We also demonstrated the role of mTOR for cell proliferation in the NCC-derived O9 cells
by using rapamycin, a well-characterized mTORC1 inhibitor, to suppress mTOR activity in
NCCs in a culture system (Fig 5N–5R). Rapamycin treatment significantly reduced p-S6K lev-
els in 24 hours, confirming its role of suppressing mTORC1 activity (Fig 5Q). O9 cells reached
80% confluence after two days in culture, whereas rapamycin-treated cells expanded slowly
and reached only 50% confluence (Fig 5N–5P). Cell live/death analysis did not reveal a signifi-
cant difference between the two groups (Fig 5R). PHH3 staining showed reduced percentage
of mitotic cells in rapamycin treated cells, corroborating that cell proliferation was reduced
upon rapamycin treatment (Fig 5R).
We further characterized primary NCCs isolated from the first pair of PAs of E9.5 mice.
Consistent with in vivo observation, mTOR-deficient NCCs expanded slowly in culture and
displayed altered morphology compared to controls (Fig 5S). Phalloidin and PHH3 staining
revealed reduced cytoskeleton and decreased number of PHH3+ cells in mTOR-deficient cells
(Fig 5T and 5U). Altogether, these results support that the mTOR pathway is critical for NCC
proliferation and survival.
Disruption of mTOR causes hyperactivity of P53 in the facial primordia
and lowering P53 activity attenuates craniofacial phenotype in NCC-mTOR
cKO mice
P53 is important for NCC development and P53 activity is elevated in a variety of developmen-
tal disorders [31–37]. Here we found that levels of P53 and its downstream factor P21 were
markedly elevated in the facial primordia of NCC-mTOR cKO mice (Fig 6A–6D). Further-
more, levels of Mdm2, a negatively regulator of P53 through physical binding [38, 39], were
significantly decreased (Fig 6A and 6B). Hyperactivity of P53 and P21 might account for the
mTOR for Neural crest cells
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Fig 4. Initial NCC migration and PA morphogenesis. (A, B) Sagittal sections of E9.0 embryos (15-somite stage). (C)
Quantification of the number of NCCs at E9.0 stage. (D, E) E9.5 embryos observed by a fluorescent microscope. Green
fluorescence (GFP) labels NCCs; red fluorescence (tdTomato) labels non-NCCs. (F, G) E10.5 embryos observed by a
fluorescent microscope. (H, I) Dark field observation of E10.5 embryos. (J) Quantification of GFP fluorescence
intensity of E9.5 and E10.5 mice. fn: frontonasal prominence; ht: heart: ns: non-significant; pa: pharyngeal arch. Scale
bars: 100 μm.
https://doi.org/10.1371/journal.pgen.1007491.g004
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Fig 5. Apoptosis and proliferation assays. (A-D) Apoptosis at E10.5 and E11.5. (E) Quantification of apoptotic cells. (F, F’) Dual staining of TUNEL and Runx2
shows that apoptotic cells are predominantly NCC descendants. (G, H) Immunofluorescence for PHH3 in E10.5 facial primordia. (I, J) Immunofluorescence for PHH3
in the FN at E11.5. (K, L) Immunofluorescence for PHH3 in the mandibular arch at E11.5. Arrowheads indicate groove in the tongue. (M) Quantification of PHH3
+ cells. (N, O) O9 NCCs cultured with and without rapamycin (100nM). (P) PHH3 staining of O9 cells. (Q)Western blot for mTORC1 downstream target p-S6K1/
S6K1 upon rapamycin treatment. (R) Percentage of PHH3+ cells and cell live/death assay. (S) Phase contrast images of cultured PA cells. (T) Phalloidin and Dapi
staining of PA cells. (U) PHH3 and Phalloidin double staining of PA cells. br: brain; ctr: control; fn: frontonasal prominence; md: mandibular prominence; mx:
maxillary prominence; rapa: rapamycin; ton: tongue. Scale bars in (A-D): 100 μm.; scale bars in (L-U): 200 μm; scale bar in (L) applies to (G-K).
https://doi.org/10.1371/journal.pgen.1007491.g005
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observed apoptosis and cell cycle arrest. Interestingly, we observed cytoplasmic accumulation
of P53 in mutants, suggesting potential transcription-independent functions of P53 (Fig 6C
and 6D). We therefore examined additional markers for the P53-dependent pathways includ-
ing Bax and β-galactosidase, whose activities are associated with mitochondrial apoptosis (the
intrinsic apoptosis pathway) and cell senescence respectively. Results showed that Bax levels
were significantly elevated in mutants, implying that P53 induces cell death, at least in part, via
the intrinsic apoptotic pathway (Fig 6A and 6B). β-galactosidase antibody staining failed to
reveal any positive cell in mutant facial primordia up to the stage of E13.5, when craniofacial
development had been arrested. By E14.5, however, we detected a number of β-galactosidase
positive cells in mutant facial primordia, in contrast to virtually no positive cells in controls
(Fig 6E, 6F and 6G). These results suggest that cell senescence was a late and uncommon event
of mTOR deficiency.
We next sought to determine if lowering P53 activity would be able to rescue the defects in
NCC-mTOR cKO mice. We performed one copy reduction of P53 in NCC-mTOR cKO mice
by establishing the Wnt1-Cre;mTOR loxp/loxp; P53+/- mice. Results showed that P53 haplodefi-
ciency caused a mild craniofacial phenotype in mTOR cKO mutants at E12.5, as evidenced by
more pronounced snouts than P53+/+ mutants (Fig 7A). Sectional examination confirmed
Fig 6. Hyperactivity of P53 signaling in the NCC-mTOR KO mice. (A) Western blots for Mdm2, P53, P21 and Bax
of E10.5 and E11.5 facial primordia. (B) Quantification of western blots of Mdm2, P53, P21 and Bax. (C, D)
Immunofluorescence for P53 in the mandibular prominence of E10.5 mice. (E, F) Immunofluorescence for β-
galactosidase in the mandibular arch of E14.5 mice. Note, a number of positive cells are present in mutant mandibular
arch. (G) Quantification of β-galactosidase positive cells. P<0.01. β-gal: β-galactosidase; ctr: control; md: mandible;
oe: oral epithelium; tb: tooth bud; ton: tongue. Scale bar: 100μm.
https://doi.org/10.1371/journal.pgen.1007491.g006
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improved development of the snouts (Fig 7B, 7C and 7D). Development of the anterior basi-
cranium was also ameliorated by a copy-reduction of P53 (Fig 7C). However, midline growth
deficiency and defective organogenesis persisted, i.e. missing of cartilages, grooved tongue
and vascular dilation (Fig 7C). In addition, cell proliferation in the facial primordia, although
increased compared to P53+/+ mutants, were not elevated to a normal level, implying that hap-
lodeficiency of P53 was not sufficient to fully rescue the proliferation defect in mutants (Fig 7E
and 7G). Remarkably, the proportion of apoptotic cells in mTOR cKO mutants was signifi-
cantly reduced by P53 haplodeficiency (Fig 7F and 7G).
Dissecting functional roles of mTORC1 and mTORC2 for NCCs
To know relative contributions of mTORC1 and mTORC2 in NCCs, we continued to perform
NCC knockout of Rptor (NCC-Rptor cKO) and Rictor (NCC-Rictor cKO), the core compo-
nents in mTORC1 and mTORC2 respectively. The majority of the NCC-Rictor cKO mice died
shortly after birth with relatively mild craniofacial defects. Mutant mouse developed a thin
face with a small snout and a short lower jaw (Fig 8A and 8B). Skeleton preparation by alizarin
Fig 7. Lowering P53 activity by P53 copy reduction attenuates the craniofacial phenotype in the NCC-mTOR cKO mice. (A) Gross
examination of NCC-mTOR cKO mice by P53 copy deduction. (B) Alcian blue staining in parasagittal sections of E12.5 heads. (C)
Histology in frontal sections of E12.5 heads. (D) Quantification of the length of snout/frontonasal prominence, which is represented by
the length from the brain-nose turning point to the most anterior plane of the snout. (E) PHH3 staining in frontal sections of E11.5 FN.
(F) Apoptosis in frontal sections of E11.5 heads (arrow heads). (G, H) Quantification of cell proliferation and apoptosis.  P<0.05;
P<0.01. bc: basicranium; br; brain; ctr: control; fn: frontonasal prominence; ls: length of the snout; mc: Meckel’ cartilage; md:
mandibular arch; mx: maxillary arch; ne: nasal epithelium; pl: palatal shelf; sn: snout; tb: tooth bud; ton: tongue; vd: vessel dilation. Scale
bar: 200μm.
https://doi.org/10.1371/journal.pgen.1007491.g007
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Fig 8. Craniofacial development of the NCC-Rictor and NCC-Rptor cKO mice. (A) Lateral and top view of mouse heads at the newborn stage. (B)
Quantification of snout length (the most anterior point to the most anterior eye line) and width (the line at the mid-point of the length line), p<0.05. (C, D, E)
Skeleton preparation by alizarin red and alcian blue staining at the newborn stage, demonstrating hypoplasia of the craniofacial bones and an enlarged
interfrontal suture in the mutant. (F, G) Immunofluorescence for PHH3 in the first PA. (H) SEM of the NCC-Rptor cKO mouse heads. (I) Western blots for p-
S6K1,S6K1, p-4E-BP1, 4E-BP1, Cyclin D1, Vegf, c-Myc, p-Akt, Akt, p-Erk, Erk, and Gapdh of E11.5 facial primordia,  p<0.05. boc: basioccipital bone; cd:
condyle of the mandible; cs: coronal suture; ctr: control; fr: frontal bone; ic: incisor; inf: interfrontal suture; is: lambdoid suture; mx (max in H): maxilla; pmx:
premaxilla; nb: nasal bones; ns: non-significant; oc: occipital bone; par: parietal bone; sn: snout; jaw;l: lower jaw; sp: sphenoid bone; ss:sagittal suture; ts: tooth
socket; zy: zygomatic arch. Scale bar in (A): 500μm; scale bars in (G.H): 100 μm.
https://doi.org/10.1371/journal.pgen.1007491.g008
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red and alcian blue staining showed that mutant facial bones were smaller than controls (Fig
8C–8E). Development of NCC-derived frontal bones was retarded and the interfrontal sutures
were enlarged in mutants (Fig 8C). The coronal and sagittal sutures, by contrast, were nar-
rowed compared to controls (Fig 8C). Mandibular hypoplasia was evident (Fig 8E). However,
examination at embryonic stages revealed no obvious change in gross morphology, cell prolif-
eration and apoptosis during craniofacial development (Fig 8F and 8G).
By sharp contrast, the majority of the NCC-Rptor cKO mice died at E12.5, exhibiting a full
spectrum of defects in craniofacial morphogenesis and organogenesis phenocopying these
seen in NCC-mTOR cKO mice (Fig 8H, and S3 Fig). These two mutant genotypes showed
markedly reduced activation of the mTORC1 downstream factor S6K1 and 4e-BP1 from the
facial primordia (Fig 8I). Protein levels of a set of cell cycle and signaling molecules, including
Cyclin D1, c-Myc, p-Akt/Akt, p-Erk and Vegf were all reduced (Fig 8I). Altogether, these
genetic models demonstrated that mTOR principally acts through mTORC1 for cranial NCC
development during embryogenesis.
Discussion
The functions and the underlying regulatory network of mTOR for NCC development remains
to be elucidated. Multiple lines of evidence suggest a potential link of the mTOR and P53 path-
ways in diverse settings [34, 35, 40–42]. In a variety of contexts, P53 suppresses mTOR activity
and inhibits cell proliferation [34]. In cranial NCC development, maintaining a proper level
of P53 is of critical importance [31, 43]. Hyperactivity of P53 and lowered function of mTOR
have been demonstrated in a number of human genetic diseases, such as the Roberts syndrome
and Treacher Collins syndrome, which are featured by facial hypoplasia due to a cell prolifera-
tion defect [32, 33]. On the other hand, mTOR activation and P53 dysfunction are common
events in the development of many types of cancers [44]. Elevated P53 levels in our mTOR
cKO model imply that there may also exist a negative feedback loop between the mTOR and
P53 pathways.
Although it has been firmly established that P53 inhibits the mTOR pathway through regu-
lation of TSC1/TSC2, both of which are negative regulators of mTOR5, 36, 40, 41, the mechanism
by which mTOR feedbacks to P53 remains to be revealed. Although reduced levels of P53
inhibitory regulators, such as Pax3, Mdm2 and p-Akt, may in part account for the P53 stabili-
zation and accumulation in mutant mice [38, 39, 45], potential cellular stresses caused by
mTOR deletion may be able to directly activate P53. Multiple lines of evidence point to a possi-
ble convergence of the mTOR and P53 pathways in the process of ribosome biogenesis, in
which mTOR plays a critical role and whose stress causes P53 activation [6–9, 46].
Activation of P53 explains the upregulation of P21 and Bax, which further induces cell
cycle arrest and activation of the intrinsic apoptosis pathway. Apoptosis, although increased
in mutants, was only rampant at a stage when defective morphogenesis was already obvious.
Thus, increased apoptosis is not likely a primary cause for abnormal development. Rather, it
may be secondary to the cellular defects of nutrition acquiring, signal responding to the local
developmental niche, and cellular stresses caused by mTOR deficiency. Despite of large num-
bers of cell death, a considerable amount of NCCs survived in the mutant facial primordia and
entered into cell cycle arrest. Reduced apoptosis in P53 haplodeficincy mutants further corrob-
orates that mTOR regulates survival of NCCs, at least in part, through interacting with the
p53-dependent pathways.
However, lowering P53 activity, although promoted cell proliferation, failed to fully rescue
the proliferation defect, and midline cleft remained in all mutants. β-galactosidase staining
indicates that the majority of mutant NCCs were not yet in a senescence status. These results
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together point to the fact that additional mechanisms may also be at play accounting for the
observed phenotype. Indeed, we found that levels of a number of important signaling and cell
cycle molecules were reduced in mutants, including Vegf, Cyclin D1 and c-Myc. Individual
NCC knockout of the genes that encode these proteins show mild craniofacial abnormalities
compared to the NCC-mTOR cKO mice, suggesting that the phenotype in NCC-mTOR cKO
mice is a combinational effect of multiple protein level changes [26, 47, 48].
In addition to these firmly established roles for cell proliferation and survival, mTOR is
also critical for NCC differentiation. A major fate for cranial NCCs is to differentiate into
skeletal cells including chondroblasts and osteoblasts, which form cartilages and bones
respectively during craniofacial development. In NCC-mTOR cKO mice, NCC-derived carti-
lages, including the nasal cartilage, Meckel’s cartilage and anterior basicranium, were absent.
We even failed to detect the chondrogenic marker Sox9 in the facial primordia of NCC-
mTOR cKO mice, suggesting that mTOR is essential for chondrogenic differentiation of
NCCs. This is in stark contrast with a previous study, showing the presence of cartilage
precursors for endochondral bones of mesoderm origins [10]. Thus, mTOR is differently
required for chondrogenic differentiation by NCCs and mesoderm-derived mesenchymal
cells.
In contrast to chondrogenesis, NCC-mTOR cKO mice did show osteogenic differentiation
in the facial primordia, as indicated by positive staining of Runx2 and ALP although at reduced
levels. This implies that the roles of mTOR for cell differentiation depend on a specific context.
However, bone matrix, which was abundant in controls, was barely detectable in mutants,
suggesting that mutant osteoblasts failed in collagen synthesis. This is consistent with the
observation in mesoderm-derived bones in a previous study [10]. Critical functions of mTOR
for osteogenesis are further corroborated by an mTOR hyperactivity model, in which excessive
bone formation and bone sclerosis were observed in NCC-derived bones [23].
NCCs regulate angiogenesis and in situ vascularization in NCC-derivatives through
expressing Vegf and by directly differentiating into SMCs [26]. In NCC-mTOR cKO mice, α-
SMA+ cells appeared functionally insufficient and often failed to form a complete SMC layer
for the vasculature. As a result, vessel dilation and bleeding due to rupture were common.
However, vascular defects were only detectable from the stage of late E11.5, when retarded
facial development was already apparent. These results suggest that altered craniofacial mor-
phogenesis is a primary defect occurring prior to vascular abnormality.
By analysis of Rptor and Rictor NCC cKO models, we demonstrate NCC-Rptor disruption
caused a spectrum of defects mirroring that of the NCC-mTOR deletion, suggesting that
mTOR mainly acts through mTORC1 for embryonic craniofacial development. By contrast,
functions of mTORC2 are not critical for cell proliferation, survival and differentiation, and
are dispensable for early craniofacial morphogenesis and growth. However, the mild craniofa-
cial phenotype of mTORC2 disruption mice at the postnatal stage suggests that mTORC2
plays a role in regulating the size of craniofacial skeletons, and may have other unknown func-
tions in maintaining tissue homeostasis. Hypoplasia of craniofacial skeletons seen in mTORC2
disruption mice is a hallmark in a variety of human genetic disorders [32, 33]. The roles of
mTORC2 for postnatal growth and homeostasis of craniofacial organs are worthy of further
investigation.
In summary, in this study we unveil critical roles of mTOR for NCC development by phe-
notypic analysis of multiple genetic models of the mTOR pathway. We show that mTOR is
required for multiple developmental processes of post-migratory NCCs, including prolifera-
tion, survival and differentiation in a variety of organ systems and by regulating a number of
signaling pathways. Significantly, we reveal that hyperactivity of P53 serves as an important
mechanism among others underpinning abnormal craniofacial development. We also
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demonstrate that mTOR acts principally through the mTORC1 pathway for embryonic cra-
niofacial development and growth.
Materials and methods
Ethics statement
Mouse experiments were approved by Columbia University Institutional Animal Care and
Use Committee (protocol number AC-AAAS0552.
Generation of tissue specific knockout models for mTOR, mTORC1 and
mTORC2
Wnt1-cre (No.022501) and mTOR loxp/loxp (No.011009), Rictor loxp/loxp (No.020649), Rptor loxp/loxp
(No. 013188), P53+/- (002101) and Rosa nT-nG (No.023035) mice were purchased from The
Jackson Laboratory [18, 24, 49–51]. Rosa26-LacZmouse was described elsewhere [52]. Mouse
genotyping was performed by general PCR procedures, using GoTaq Green Master Mix (Pro-
mega, Catalog number M7122). We used littermate wild type mice as controls unless otherwise
described.
SEM, histology, immunofluorescence, and in situ hybridization
Embryos for SEM were fixed in 2.5% glutaldehyde and dehydrated in a series of graded serial
ethanol solutions. Frontal sections of paraffin-embedded tissues were used in this study unless
otherwise described. Frozen sections were used for NCC lineage tracing and Alp staining.
ALP-stained sections were co-stained with alcian blue. Specifically, sections were incubated in
ALP buffer for 15 minutes and then incubated in a NBT/BCIP solution (Thermo Fisher Scien-
tific, Catalog number 4072) until the color reaction was desirable. The sections were next
stained with an alcian blue. Whole mount LacZ staining was performed according to previ-
ously described procedures, lacZ-stained embryos were sectioned and count-stained with
Nuclear Fast Red solution (Vector, catalog number H-3403) [28]. Picrosirius red staining was
performed following the manufacturer’s protocol (Abcam, catalog number ab150681).
Heat-induced antigen retrieval was applied for immunofluorescence. Deparaffinized sec-
tions were heated in 1x antigen unmasking solution (Vector, catalog number H-3301) at 100
˚C for 45 minutes. Antibodies for phospho-mTOR (phospho-S2448; Abcam, ab109268), AP-
2α (Abcam, ab189995), beta-catenin (Abcam, ab6302), p-Smads1/5/8 (Millipore, AB3848-I),
Runx2 (Abcam, ab76956), OCN (Abcam, ab93876), Sox9 (Abcam, ab26414), α-SMA (Abcam,
ab124964), CD31 (Abcam, ab7388), 3A10 (DSHB, supernatant), Vimentin (Abcam, ab92547),
pan-keratin (Abcam, ab8068), P53 (Santa cruz, sc-71819), and β-galactosidase (Invitrogen, 14-
6773-81) were used. Alexa Fluror 488 and Alexa Fluror 555 secondary antibodies were used
for signal detection (Thermo Fisher Scientific). Antibody dilation followed the manufacturer’ s
recommendations. Primary antibody was incubated overnight at 4 ˚C, secondary antibody
was incubated at room temperature for 2 hours. Fluorescence signaling quantification was per-
formed by calculating average fluorescence intensity of the signal channels using the Image J
software (National Institutes of Health) in accordance with the recommended guidelines.
Whole mount in situ hybridization was performed as previously described [28]. Digoxi-
genin-labeled riboprobes of Alx3, Msx1, Pax3 and Fgf8were generated by in vitro transcription
using a kit from Roche (Catalog number 10999644 001) [28]. A NBT/BCIP solution was used
for color reaction. Each probe staining was performed at least on three embryos of each geno-
type. Staining of the images were quantified with image J. Stained areas were selected by
threshold adjustment of the signal channels.
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Apoptosis and proliferation assay
Paraffin sections were used for TUNEL staining and proliferation assays. TUNEL staining for
apoptosis was performed using the DeadEnd TUNEL System (Promega, G3250), following the
manufacturer’s protocol. The fraction of apoptotic cells over total number of cells was used for
apoptosis index. PHH3 staining was used for proliferation assay (Millipore, 06–570). The frac-
tion of PHH3 positive cells over total number of cells was used for proliferation index. Repre-
sentative and comparable sections from three independent samples of each genotype were
used for assessment.
Cranial NCC culture
Primary NCCs were isolated from the first PA of E9.5 mice. Briefly, the first pair of PAs were
dissected off and digested with Dispase to remove the epithelia. Mesenchyme was further
digested with a collagenase solution, and cultured in a stem cell medium containing 15%
serum and 100ng/ml Fgf2 (Millipore, GF003). O9 cells were purchased from the Millipore and
maintained following manufacturer’s recommendations [53]. Approximately 50,000 cells were
seeded per well in a 6-well plate. Live/death assay was performed using a detection kit follow-
ing manufacturer’s protocol (Thermo Fisher, L3224). A serial of concentrations of rapamycin
(Cell signaling, catalog number 9904) (10nM, 50nM, and 100nM) were applied. All experi-
ments were performed in triplicates.
Western blot assay
Cell lysates for western blots were prepared from cultured NCCs. Specifically, NCCs, seeded
in 6-well plates, were collected and lysed with RIPA buffer for half hour at room temperature
and then centrifuged at 11500 rpm for 20 minutes. Supernatants were used for western blots.
Lysates of mouse samples were prepared from E10.5 and E11.5 facial primordia. The facial pri-
mordia of two embryos were dissected off, homogenized, lysed in 100μm RIPA buffer for 1
hour, and centrifuged at 11500 rpm for 20 minutes. Supernatants were collected for western
blots, and 25μl lysate per sample was loaded per lane. Antibodies for p-S6K (phospho-T389;
Abcam, ab2571), S6K (Abcam, ab32529), p-4eBP1 (phospho-Thr 45; Santa cruz, sc-271947),
4eBP1 (Santa cruz, sc-9977), Vefg (Santa cruz, sc7269), p-Akt1 (phospho-Thr 308; Santa cruz,
sc-135650), Akt1(Santa cruz, sc-135829), p-Erk1/2 (phospho-Thr 202 and phospho-Tyr 204;
Santa cruz, sc-81492), Erk1/2 (Santa cruz, sc-135900), c-Myc (Abcam, ab32072), P21 (Santa
cruz, sc-6246), P53 (Santa cruz, sc-71819), Mdm2 (Santa cruz, sc-965), Bax (Santa cruz, sc-
23959), β-tubulin (Santa cruz, sc-101527) and Gapdh (Santa cruz, sc-47724) were used. IRDye
secondary antibodies were used for signal detection (Abcam). Antibody dilation followed
manufacturer’s recommendations. All experiments were repeated 3 times each. Western blot
bands were quantified with Image J.
Statistical analysis
Quantification of tissue sections were performed by analyzing three independent biological
samples, two representative and comparable sections for each. Quantification of western
blot was performed by analyzing three technical replicates. Quantification was performed by
two-tailed t-test and one-way ANOVA with post-hoc tests using Microsoft Excel software.
Data was presented as means and standard deviation. P<0.05 was regarded as statistically
significant.
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Supporting information
S1 Fig. mTOR expression at successive stages. (A, B) Immunofluorescence for p-mTOR of
the first PA at E9.5. (C, D) Immunofluorescence for p-mTOR at E11.5. (E, F) Immunofluores-
cence for p-mTOR at E14.5. br: brain; mc: Meckel’ s cartilage; md: mandible; msc: mesenchy-
mal condensate; nf: neurofilament; pa: pharyngeal arch; tb: tooth bud; ton: tongue. Scale bar:
100 μm.
(TIF)
S2 Fig. Defective development of the submandibular gland and mandibular first molar.
(A, B) Gross examination of the submandibular gland with a fluorescent microscope at E13.5.
(C, D) Mandibular first molar stained with pan-keratin. Development of mutant molar is
arrested at the bud stage. pan-k: pan-keratin; m1: the first molar; smg: submandibular gland.
Scale bar: 100μm.
(TIF)
S3 Fig. Defective craniofacial development in NCC-Rptor cKO mice. (A, B) Lateral view of
E11.5 embryos. (C-F) Lateral and frontal view of E13.5 embryos. Arrowheads in (F) indicate
midline cleft in the mutant. (G) Quantification of P53 levels of E11.5 mouse facial primordia,
P<0.05. (H, I) PHH3 staining at E10.5. (J, K) Apoptosis at E11.5. (L) Quantification of PHH3
+ cells and apoptotic cells, p<0.01. br: brain; fn: frontonasal prominence; md: mandibular
prominence; mx: maxillary prominence: pal: palate; sn: snout; ton: tongue. Scale bar (A-F):
500 μm; (G-J): 100 μm.
(TIF)
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